Anzeige
Mehr »
Donnerstag, 23.10.2025 - Börsentäglich über 12.000 News
Das Comeback des Goldrauschs - diesmal ausgelöst durch eine Währungskrise
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2ACV2 | ISIN: ES0167733015 | Ticker-Symbol: ORN
Tradegate
23.10.25 | 15:09
3,185 Euro
-2,15 % -0,070
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ORYZON GENOMICS SA Chart 1 Jahr
5-Tage-Chart
ORYZON GENOMICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
3,1753,25522:58
3,1753,25022:00

Aktuelle News zur ORYZON GENOMICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoOryzon Genomics - Making headway towards Phase III in BPD204Oryzon Genomics has announced that it has received FDA feedback on its plans for the Phase III programme in borderline personality disorder (BPD) for its lead central nervous system (CNS) drug candidate...
► Artikel lesen
ORYZON GENOMICS Aktie jetzt für 0€ handeln
FrOryzon Genomics: FDA gibt Feedback zu Phase-III-Studienprotokoll für Vafidemstat2
FrFDA provides feedback on Oryzon's vafidemstat BPD trial protocol7
FrOryzon Genomics, S.A.: ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder145Provides clarity on the aspects to incorporateCompany to address them and resubmit revised protocol MADRID, Spain and CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN...
► Artikel lesen
01.10.Oryzon Genomics, S.A.: ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors115MADRID and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and European leader in epigenetics,...
► Artikel lesen
16.09.Oryzon Genomics, S.A.: ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant4
27.08.EMA authorises "Restore", Oryzon Genomics' Phase Ib clinical trial on iadademstat in sickle cell anaemia (SCA)4
26.08.Oryzon Genomics - Foray into sickle cell disease351Oryzon Genomics has announced that the European Medicines Agency (EMA) has provided regulatory clearance for a Phase Ib trial of iadademstat in sickle cell disease. The Phase Ib study (named RESTORE)...
► Artikel lesen
25.08.Oryzon Genomics, S.A.: ORYZON Receives European Medicines Agency Approval to Initiate a Phase Ib Study of Iadademstat in Sickle Cell Disease195First iadademstat clinical trial in non-malignant hematological indications MADRID and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker:...
► Artikel lesen
31.07.Oryzon Genomics - Making headway rolling into H225433Oryzon Genomics has reported its Q225 results, summarising an active period. Its programme focused on vafidemstat in borderline personality disorder (BPD) remains a strategic priority, with the Phase...
► Artikel lesen
14.07.Oryzon Genomics, S.A.: ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat1
11.07.Oryzon Genomics - KOL event highlights vafidemstat potential in BPD382At Oryzon Genomics' key opinion leader (KOL) event, vafidemstat's path through Phase III in borderline personality disorder (BPD) was laid out. The significant unmet need was highlighted, as there are...
► Artikel lesen
27.06.ORYZON GENOMICS, S.A.: ORYZON announces the voting results from its Ordinary General Shareholders' Meeting1
25.06.Oryzon Genomics, S.A.: ORYZON to Host Virtual KOL Event on July 9, 20251
24.06.Oryzon Genomics - A step closer to a new treatment paradigm in BPD385Oryzon Genomics has submitted the Phase III clinical trial protocol to the FDA for its lysine-specific demethylase 1 (LSD1) inhibitor, vafidemstat, in borderline personality disorder (BPD), marking...
► Artikel lesen
23.06.Oryzon Genomics, S.A.: ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) Patients184PORTICO-2 designed to validate vafidemstat's efficacy in reducing aggression in BPD patientsPrimary endpoint: STAXI-2 Trait Anger (patient-reported)Key secondary endpoint: Overt Aggression Scale-Modified...
► Artikel lesen
23.06.ORYZON GENOMICS, S.A.: ORYZON announces the submission to the FDA of the clinical trial protocol for its Phase III PORTICO-2 trial of vafidemstat in Borderline Personality Disorder patients2
17.06.Oryzon Genomics, S.A.: ORYZON to Attend the 2025 Phelan-McDermid Syndrome (PMS) Congress in Barcelona on June 26-293
27.05.Oryzon Genomics, S.A.: ORYZON to Provide Corporate Progress Updates at Several Events in May-June1
26.05.ORYZON GENOMICS, S.A.: Call of the Ordinary General Shareholders' Meeting of Oryzon Genomics, S.A.2
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1